Boji Pharmaceutical: Received Drug Clinical Trial Approval Letter

Boji Pharmaceutical announced that its recently declared drug "FCZR" has obtained the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The notice numbers are 2025LP02257 and 2025LP02258, the drug name is FCZR, and the indication is ear fungal disease. The registration classification is chemical drug class 2.2/2.4. The approval conclusion is to proceed with clinical trials. FCZR formulation has advantages in fluidity and ease of administration, and currently there are no similar drugs approved for marketing domestically or internationally. The acquisition of the "Drug Clinical Trial Approval Notice" this time is a milestone achievement in new drug development and will not have a significant impact on the company's operating performance.